These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results
Portfolio Pulse from Lisa Levin
Vertex Pharmaceuticals reported Q3 earnings of $4.08 per share, beating estimates of $3.98. However, sales of $2.48 billion missed estimates of $2.50 billion. The company revised its FY23 sales forecast to $9.85 billion. Following the earnings announcement, several analysts adjusted their price targets for Vertex. The company's shares fell 0.6% to $383.51 on Tuesday.
November 07, 2023 | 6:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Vertex Pharmaceuticals beat Q3 earnings estimates but missed on sales. The company revised its FY23 sales forecast. Several analysts adjusted their price targets for Vertex, which could influence the stock's performance.
The mixed Q3 results and revised FY23 sales forecast could have a neutral impact on Vertex's stock in the short term. While the earnings beat is positive, the sales miss and lowered forecast could be seen as negatives. The adjusted price targets from analysts could influence investor sentiment and the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100